Lankenau Heart Institute, Main Line Health, Names Gianluca Torregrossa, MD, Director of Robotic Coronary Revascularization
(Wynnewood, PA, July 16, 2021) Lankenau Heart Institute, part of Main Line Health, has named Gianluca Torregrossa, MD, Director of Robotic Coronary Revascularization. Dr. Torregrossa is an academic cardiac surgeon dedicated to evidence-based, state-of-the-art practice in advanced coronary revascularization. Skilled in all aspects of cardiac surgery, he specializes in robotic-assisted coronary artery bypass graft (CABG) surgery and hybrid coronary revascularization in collaboration with interventional cardiology colleagues.
“We are particularly pleased to have Dr. Torregrossa join Francis Sutter, DO, FACS, at Lankenau Medical Center, which remains the nation’s busiest robotic coronary revascularization program,” says Basel Ramlawi, MD, System Chief of Cardiac Surgery, Main Line Health and co-director of the Lankenau Heart Institute. “The combined expertise of Drs. Torregrossa and Sutter in off-pump, robotic-assisted as well as traditional CABG surgery solidifies our reputation as a major referral center for patients needing coronary revascularization.”
In this newly established role, Dr. Torregrossa will continue to reinforce robotic approaches to coronary artery disease (CAD) and work to expand access to safe, effective, and durable treatment of CAD using the most appropriate and least invasive approach possible for each patient, based on new technology and research. He is dedicated to tailoring each patient’s care to minimize trauma and complications of surgery and to maximize survival and quality of life.
“We are thrilled to have Dr. Torregrossa join the cardiovascular team, and specifically the coronary program, at Main Line Health,” says Francis Sutter, DO, Chief of Cardiac Surgery, Lankenau Medical Center. “His extensive technical expertise and research background further enhance our ability to provide minimally invasive robotic-assisted coronary surgery to patients throughout the region and beyond.”
A native of Italy, Dr. Torregrossa earned his medical degree at University of Padua, where he went on to train in cardiothoracic surgery. In his final year of residency, he worked alongside retired cardiac surgeons from across Europe, treating young patients with congenital and rheumatic heart disease at Salam Centre for Cardiac Surgery in Khartoum, Sudan.
Dr. Torregrossa continued his adult cardiac surgery training in the United States with a 3-year fellowship in advanced mitral valve surgery at Mount Sinai Hospital in New York, followed by a faculty position at Mount Sinai St. Luke’s (now Mount Sinai Morningside), where he trained in several areas of advanced and robotic heart surgery, ultimately with a focus on complex, minimally invasive and robotic CABG. Dr. Torregrossa then served as Associate Director of Robotic Heart Surgery at Mount Sinai St. Luke’s before joining the section of cardiac surgery at University of Chicago Medicine. There, he was exposed to some of the most sophisticated robotic heart surgery performed in the United States and gained expertise as one of a few surgeons in the country skilled in robotic totally endoscopic coronary artery bypass (TECAB) surgery.
Dr. Torregrossa has published more than 70 peer-reviewed scientific papers in the field of cardiac surgery, is a peer reviewer for more than 5 major medical journals and serves on the editorial board of JACC Case Reports and Journal of Cardiac Surgery. He is a frequent invited speaker at national and international conferences and symposia and is highly active on social media, promoting scholarly exchange within an international community of cardiac surgeons and cardiovascular specialists on a wide variety of topics.
About Main Line Health
Founded in 1985, Main Line Health is a not-for-profit health system serving Philadelphia and its suburbs. Main Line Health's commitment — to deliver safe, high-quality, equitable and affordable care for treating and curing disease, playing an important role in prevention and disease management, as well as training physicians and other health care providers — reflects our intent to be the region's premier choice for clinical care, research, and education. A team of more than 13,000 employees and over 3,500 employed and independent physicians and advanced practice providers care for patients throughout Main Line Health.
At Main Line Health's core are four of the region's most respected acute care hospitals — Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital — as well as one of the nation's premier facilities for rehabilitative medicine, Bryn Mawr Rehab Hospital.
Main Line Health also includes Mirmont Treatment Center for drug and alcohol recovery; Main Line Health HomeCare & Hospice, which includes skilled home health care, hospice and home infusion services; Main Line Health Centers, primary and specialty care, lab and radiology, and other outpatient services located in Broomall, Collegeville, Concordville, Exton, King of Prussia and Newtown Square; Lankenau Institute for Medical Research, a biomedical research organization; and Main Line HealthCare, one of the region's largest multispecialty physician networks.
Main Line Health is the recipient of numerous awards for quality care and service, including the prestigious American Hospital Association Quest for Quality Prize, highest tier ratings from the Centers for Medicare & Medicaid Services (CMS) for Overall Hospital Quality and systemwide recognition in the 2023-2024 U.S. News & World Report Best Hospitals rankings. Main Line Health is committed to creating an environment of diversity, respect, equity and inclusion, has proudly received awards in this area and has embraced the American Hospital Association's #123forEquity Pledge to Act to eliminate disparities in care. We are dedicated to advancing patient-centered care, education and research to help patients stay healthy and live their best lives.
For more information, visit mainlinehealth.org and connect with us on social media:
About Lankenau Heart Institute
The Lankenau Heart Institute is Main Line Health's premier comprehensive cardiovascular medicine and surgery program. Lankenau Heart Institute brings together the clinical expertise of all four Main Line Health acute care hospitals and both the employed and community cardiology practices to ensure that patients receive a level of quality, service and experience that is unparalleled in the region. Through the systemwide coordination of services, Lankenau Heart Institute delivers preventive, diagnostic, therapeutic and rehabilitative cardiovascular services at each of our locations including Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital.
Lankenau Heart Institute continues to be an innovator in the use of beating-heart techniques and robotic-assisted procedures for coronary artery revascularization, minimally invasive and transcatheter approaches for valve repair and replacement, complex aortic surgery and heart rhythm disorders. With our growing experience and focus on minimally invasive techniques, Lankenau Heart Institute has expanded participation in clinical trials year after year. Our physicians are frequently invited to participate in clinical/medical device trials, many of which are designed to facilitate the use of minimally invasive approaches and procedures.
With a collaborative team of expert consultative cardiologists, interventional cardiologists, electrophysiologists, cardiovascular surgeons and specially trained advance practice nurses and technologists, Lankenau Heart Institute is dedicated to managing and treating patients with simple to complex cardiovascular disease, including heart failure, aortic disease, coronary and peripheral vascular disease, lipid and genetic abnormalities, heart rhythm disorders and valve disease. Our team of cardiologists and cardiac and vascular specialists provide patients and their families with expert cardiovascular care, close to home.